PF-543 (Citrate)
- Product NamePF-543 (Citrate)
- CAS1415562-83-2
- CBNumberCB12645149
- MFC33H39NO11S
- MW657.73
- MDL NumberMFCD23098795
- MOL File1415562-83-2.mol
- MSDS FileSDS
Chemical Properties
| form | Powder |
| color | White to yellow |
PF-543 (Citrate) Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| Biosynth QGC56283 | 25mg | $652.25 | PF 543 citrate |
Buy |
| Biosynth QGC56283 | 50mg | $1043.5 | PF 543 citrate |
Buy |
| Biosynth QGC56283 | 100mg | $1671 | PF 543 citrate |
Buy |
| ChemScene CS-1072 | 5mg | $81 | PF-543 Citrate 99.47% |
Buy |
| ChemScene CS-1072 | 10mg | $130 | PF-543 Citrate 99.47% |
Buy |
PF-543 (Citrate) Chemical Properties,Usage,Production
Uses
PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy[1][2][3].in vivo
PF-543 (1 mg/kg; intraperitoneal injection; every second day; for 21 days; female C57BL/6 J mice) treatment has no effect on vascular remodelling but reduces right ventricular hypertrophy. The protection involves a reduction in the expression of p53 and an increase in the expression of anti-oxidant nuclear factor Nrf-2[2].
Mice are initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543 for 24 h and the T1/2 is 1.2 h in blood samples. Administration of 10 mg/kg PF-543 for 24 h to mice induces a decrease in SK1 expression in pulmonary vessels[2].
| Animal Model: | Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension[2] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection; every second day; for 21 days |
| Result: | Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2. |
IC 50
SphK1References
[1] Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. DOI:10.1042/BJ20111929[2] MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28(8):946-55. DOI:10.1016/j.cellsig.2016.03.014
[3] Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047. DOI:10.1038/cddiscovery.2017.47
Preparation Products And Raw materials
PF-543 (Citrate) Suppliers
Global(49)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 | |
| 1-631-485-4226; 16314854226 |
info@bocsci.com | United States | 9920 | 65 | |
| 021-58950125 | info@chemexpress.com | China | 7545 | 61 | |
| 021-58955995 | sales@medchemexpress.cn | United States | 4853 | 58 | |
| +86-21-5821 5861 | sales@letopharm.com | China | 2374 | 58 | |
| eric_feng1954@126.com | China | 9239 | 55 | ||
| 021-65675885 18964387627 |
info@efebio.com | China | 9799 | 58 | |
| 020-61288194 61288195 | 505721671@qq.com | China | 3853 | 58 | |
| 15026964105 | 2881489226@qq.com | China | 87240 | 60 | |
| 13006575422@163.com | China | 6347 | 58 |
PF-543 (Citrate) Spectrum
1415562-83-2, PF-543 (Citrate)Related Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine